We are pleased to announce that Mathew Pletcher, Head of Rare Disease – Discovery for Roche directing early drug development and research activities for rare neuromuscular, neurodevelopmental, and ophthalmological disease, has been elected as Chair of the Companies Constituent Committee (CCC). After conducting his PhD and postdoctoral research projects, Dr Pletcher joined Pfizer Global Research and Development, eventually serving as Director of Medical Genetics for Pfizer’s Rare Disease Research Unit. Most recently, Dr Pletcher served as the Chief Science Officer for Autism, before joining Roche.
In addition, we are pleased to announce that Madhu Natarajan, Research Therapeutic Area Head for Research in Ophthalmology and Complement Biology at Shire, neurodevelopmental, and ophthalmological disease, has been elected as Vice Chair of CCC. In his role, he is responsible for setting research strategy and developing the preclinical portfolio for rare and specialized conditions in his therapeutic area. By training, Dr Natarajan is an electronics and telecommunication engineer with almost 20 years of experience in academia and industry.
Both Dr Pletcher and Dr Natarajan have been elected for a period of 3 years, starting their mandates on April 1, 2018.